PDCD1 and non-small cell lung carcinoma: The Phase I, multicohort Checkmate 012 study (NCT01454102) tested the efficacy and safety of nivolumab, a PD-1 immune checkpoint inhibitor antibody, as a stand-alone first-line treatment in 52 patients with advanced NSCLC.